Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer

Fig. 2

MC180295 and its enantiomers, MC180379 and MC180380, ability to epigenetically reactivate GFP expression in the YB5 reporter system. A Structures of MC180295 and its enantiomers, MC180379 and MC180380. Expression of GFP (measured by FACS), B 24 h, and C 4 days, after a one-time treatment of YB5 cells with MC180379, MC180380, MC180295, and a one-to-one mixture of MC180379 and MC180380. Data are shown as means ± SDs, n = 3. *p < 0.05, ***p < 0.001

Back to article page